988 related articles for article (PubMed ID: 23953907)
1. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
2. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
4. New oral anticoagulant agents - general features and outcomes in subsets of patients.
Schulman S
Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
[TBL] [Abstract][Full Text] [Related]
5. Strategies for urgent reversal of target-specific oral anticoagulants.
Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
[TBL] [Abstract][Full Text] [Related]
6. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
7. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Blann AD
Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants in atrial fibrillation.
Noll G; Noll S; Hürlimann D
Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
[TBL] [Abstract][Full Text] [Related]
10. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
11. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Levy JH
Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
14. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
15. Acute management of bleeding in patients on novel oral anticoagulants.
Siegal DM; Crowther MA
Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
17. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic interventions for reversing the effects of oral anticoagulants.
Kalus JS
Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
[TBL] [Abstract][Full Text] [Related]
19. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Lazo-Langner A; Lang ES; Douketis J
Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacological aspects of new oral anticoagulants].
Haschke M
Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]